Voyager Therapeutics Inc (VYGR) Receives $28.27 Average PT from Analysts
Voyager Therapeutics Inc (NASDAQ:VYGR) has earned a consensus recommendation of “Buy” from the fifteen ratings firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $28.00.
Several research firms have issued reports on VYGR. Canaccord Genuity reissued a “buy” rating and issued a $26.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, January 23rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $28.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 28th. ValuEngine cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Finally, Morgan Stanley began coverage on shares of Voyager Therapeutics in a research report on Friday, February 2nd. They issued an “overweight” rating for the company.
In other news, insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $13.63, for a total value of $74,828.70. Following the completion of the sale, the insider now owns 10,983 shares in the company, valued at approximately $149,698.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Dinah Ph.D. Sah sold 15,623 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total transaction of $468,690.00. Following the completion of the sale, the insider now owns 140,872 shares of the company’s stock, valued at approximately $4,226,160. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,194 shares of company stock valued at $647,757. Company insiders own 8.00% of the company’s stock.
Voyager Therapeutics (NASDAQ:VYGR) traded up $0.54 during trading on Wednesday, reaching $30.09. 506,439 shares of the company’s stock traded hands, compared to its average volume of 405,516. The stock has a market cap of $825.73 and a PE ratio of -10.60. Voyager Therapeutics has a 12 month low of $8.10 and a 12 month high of $30.83.
COPYRIGHT VIOLATION WARNING: “Voyager Therapeutics Inc (VYGR) Receives $28.27 Average PT from Analysts” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/voyager-therapeutics-inc-vygr-receives-28-27-average-pt-from-analysts/1905531.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.